Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas
Status:
Recruiting
Trial end date:
2025-09-30
Target enrollment:
Participant gender:
Summary
This is an interventional, open-label, non-randomised, multicentre, single-arm phase II
clinical trial.
Eligible patients with hepatic oligometastatic adenocarcinoma of the pancreas will receive
neoadjuvant combination chemotherapy (liposomal irinotecan, oxaliplatin, 5-fluouracil,
folinic acid (NAPOX)) in cycles of 14 days. Patients with tumour response or stable disease
and a resectable primary tumour after the first 4 cycles will undergo explorative laparotomy
and synchronous resection of the tumour and hepatic metastases, if feasible; these patients
may receive 4 more cycles of neoadjuvant chemotherapy 2-4 weeks after the explorative
laparotomy if the surgeon rated the primary tumour as non-resectable during the explorative
laparotomy.